Descrizione del progetto
Colpire i meccanismi di resistenza ai farmaci antitumorali
La resistenza alle terapie antitumorali rappresenta il principale ostacolo all’efficacia delle soluzioni di trattamento e recupero a lungo termine destinate ai pazienti oncologici. L’azienda danese Scandion Oncology sta sviluppando un nuovo farmaco (SCO-101) in grado di colpire in modo efficace vari tra i meccanismi più diffusi di resistenza molecolare al cancro. SCO-101 ha superato con successo quattro studi clinici di fase 1 effettuati su volontari sani. L’obiettivo del progetto SCANRESIST, finanziato dall’UE, è quello di condurre studi di convalida clinica in pazienti affetti da tumori resistenti ai taxani con potenziali test clinici di fase 2 in aperto allo scopo di garantire che la prova di concetto del farmaco SCO-101 risulti una modalità di trattamento sicura ed efficiente. SCO-101 rappresenta un cambiamento di paradigma che agisce tramite molteplici meccanismi al fine di interferire con la farmacoresistenza.
Obiettivo
Worldwide in 2018, cancer has been responsible for around 9.6 million deaths, and with a prediction of a further increase in incidence over the next years – which calls for urgent better treatment modalities to combat such deadly disease. Resistance to anticancer therapy is considered the main obstacle to successful clinical management of cancer patients. Scandion Oncology A/S (SCANDION) is a clinical-stage biotechnology company aimed to solve the anti-cancer drug resistance problem. We are developing a new drug, the SCO-101, which effectively targets some of the most common molecular resistance mechanisms in cancer. SCO-101 represent a paradigm shift in treatment of drug-resistant cancer, with multi mechanisms of actions in interfering with drug resistance. SCO-101 has previously passed four clinical phase I studies in healthy volunteers and proved to be a safe oral drug with very limited toxicity. The SCANRESIST project aims at performing clinical validation studies in taxane resistant breast cancer patients with open-labelled Phase II prospective clinical trial to establish SCO-101 Proof of Concept as a safe and efficient treatment modality.
Our business model is based on out-licensing SCO-101 to pharma players active in anti-cancer drugs – who will be responsible for the remaining clinical development and market launch. The Phase II clinical validation has been pointed as a critical step achieve a deal with big pharma partners/licensees, which we know are interested in novel drugs with novel MoA, and with well-designed and well-performed phase II studies with positive results. Thus, the project will not only open a large market for SCANDION as it will also allow us to position the company as a unique provider of a new generation of anti-cancer resistance drugs – continuing our path on developing other drugs to combat drug resistance in cancer, innovative trial designs, predictive biomarkers and biomarker endpoints.
Campo scientifico
Programma(i)
Argomento(i)
Invito a presentare proposte
Vedi altri progetti per questo bandoBando secondario
H2020-SMEInst-2018-2020-1
Meccanismo di finanziamento
SME-1 - SME instrument phase 1Coordinatore
2100 KOBENHAVN
Danimarca
L’organizzazione si è definita una PMI (piccola e media impresa) al momento della firma dell’accordo di sovvenzione.